A phase I trial of panobinostat and epirubicin in solid tumors with a dose expansion in patients with sarcoma

This phase I study evaluated combined panobinostat and epirubicin in patients with advanced solid tumors, establishing a MTD, and demonstrating a correlation between neutropenia, PBMC histone acetylation and clinical benefit. In a sarcoma expansion cohort, more than half of patients, having previously failed anthracycline therapy, benefited, suggesting HDAC inhibition reverses resistance.

from Cancer via ola Kala on Inoreader http://ift.tt/1oytFAH
via IFTTT